Sara Wester, MD
Ophthalmic Plastic and Reconstructive Surgery · Miami, FLNPI 1730380445
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,094 of the $77,543 with a category attached, or 74.9%. Amgen accounts for 93.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $26,623 and has fallen 71.3% since, to $7,651 in 2025.
Across 81 payments — averaging $957.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$72K
- Argenx US, Inc.$5K
- Mallinckrodt Enterprises LLC$131
- AbbVie$84
- Johnson & Johnson$43
- Mallinckrodt Hospital Products Inc.$39
- plus $116 from 5 others
Across 21 payments — averaging $46,967 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$986K
What the payments were for
- Consulting fees$13,43817%
- Speaking & faculty fees$58,09475%
- Travel & lodging$4,0025%
- Food & beverage$1,9342%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 69 | $72,330 |
| Argenx US, Inc. | 1 | $4,800 |
| Mallinckrodt Enterprises LLC | 2 | $131 |
| AbbVie | 1 | $84 |
| Johnson & Johnson | 1 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $34 |
| Biotissue Holdings Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Medtronic | 1 | $19 |
| Katalyst Surgical, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,543 in reported general payments places this provider in the 85th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 44 | $506 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 34 | $322 |
| Doxycycline Hyclate | 15 | $153 |
| ErythromycinErythromycin Base | 17 | $139 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Miami
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Catherine ChoiMiami$596
- Myron TanenbaumMiami$551
- William EvansMiami$412
- Michelle LattingMiami$352
- John FezzaVenice$3.6M
- Keshini ParbhuWindermere$102K
- Robert ApplebaumLakeland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.